Abbonarsi

Bone marrow derived mesenchymal stromal cells provide survival signals to B-cells in vitro – no major role for BAFF - 19/04/08

Doi : 10.1016/j.jbspin.2008.01.005 
T. Dallos a, c, M. Krivošíková b, c, M. Chorązy-Massalska c, E. Warnawin c, E. Záňová c, d, W. Rudnicka c, A. Radzikowska c, W. Maśliński c
a 2nd Department of Paediatrics, Comenius University, Bratislava, Slovak Republic 
b Institute of Immunology, Medical Faculty, Comenius University, Bratislava, Slovak Republic 
c Department of Pathophysiology and Immunology, Institute of Rheumatology, Warsaw, Poland 
d National Institute of Rheumatic Diseases, Piešťany, Slovak Republic 

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

AB03

Abstract

Background

Mesenchymal stromal cells (MSCs) are a unique cell type that has strong anti-proliferative effects on co-cultured activated T and B-cells in vitro. Based on our observation of significant differences between rheumatoid arthritis (RA) and osteoarthritis (OA) bone marrow B-cell compartments, we hypothesized that RA bone marrow MSCs may contribute to the pathogenesis of RA by enhancing B-cell survival.

Objectives

To compare the effect of RA and OA bone marrow derived MSCs (RA-MSCs, OA-MSCs) on the survival of healthy donor purified B-cells.

Methods

RA-MSCs (n=7) and OA-MSCs (n=5) were isolated from patients undergoing hip replacement surgery, and cultured in vitro for 2-5 passages. Washed cells were co-cultured with CD20+ B-cells for 60 hours in 17 different co-culture experiments. Cell survival was analyzed using 7-amino-actinomycin D (7AAD) labelling and flow-cytometric analysis and compared to the survival of B-cells cultured without MSCs (n=8). Expression of B-cell activating factor (BAFF) mRNA and protein was determined by RT-PCR and flow-cytomery after labelling with BAFF-specific antibodies.

Results

We observed that the presence of both RA-MSCs and OA-MSCs in the cultures significantly enhanced B-cell survival (70,11±7,28% and 54,65±11,83% viable cells, respectively) as compared to controls (35,13±13,83%, p < 0,001, Kruskal-Wallis ANOVA), the effect being more prominent in RA-MSCs (p < 0,05, Tukey-Kramer test). Both RA-MSCs and OA-MSCc displayed expression of BAFF mRNA and protein. We did not observe a convincing enhancement of BAFF mRNA expression by TNF-. Blocking BAFF signalling by specific BAFF and BAFF-R antibodies, reduced the survival of B-cells by 20%, but did not abrogate the positive effect of MSCs on B-cell survival.

Conclusions

MSC interaction with B-cells may provide additional stimuli for lymphocyte survival via an as yet unidentified factor and therefore contribute to the pathogenesis of RA. BAFF, though produced by MSCs, is of minor importance in this setting. Further studies to identify the molecular basis of our observation are warranted.

Il testo completo di questo articolo è disponibile in PDF.

 This work was supported by grant MRTN-CT-2004-005693 while Tomáš Dallos, Monika Krivošíková and Elizabeth Záňová were Marie-Curie fellows at the Department of Pathophysiology and Immunology of the Institute of Rheumatology, Warsaw, Poland.


© 2008  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 75 - N° 2

P. 243 - marzo 2008 Ritorno al numero
Articolo precedente Articolo precedente
  • The link between metastasis-associated protein S100A4 and rheumatoid arthritis
  • L. Šenolt
| Articolo seguente Articolo seguente
  • Synovial glycosidases in joint diseases
  • M. Pásztói, G. Nagy, P. Géher, T. Lakatos, K. Tóth, P. Pócza, M. Mercedesz, A. Falus, E.I. Buzas

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.